<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Fluoxetine - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../sickbay-shared.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Fluoxetine</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Neuro / Psych</div>
      <h1>Fluoxetine</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Fluoxetine 20mg Capsules</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Major depressive disorder</strong>
            <ul>
              <li>Initial: 20 mg PO once daily (typically in morning)</li>
              <li>Maintenance: 20–60 mg daily; adjust based on response and tolerance after several weeks (dose changes require provider oversight)</li>
            </ul>
          </li>
          <li><strong>Generalized anxiety disorder / panic disorder / OCD</strong>
            <ul>
              <li>Initial: 20 mg PO once daily</li>
              <li>Dose adjustments as per provider direction; may require higher doses for OCD (up to 60–80 mg daily)</li>
            </ul>
          </li>
          <li><strong>Onboard considerations</strong>
            <ul>
              <li>Typically used for continuation of established therapy (not first-line initiation at sea unless under medical direction)</li>
              <li>20 mg capsules stocked: suitable for standard maintenance dosing</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Major depressive disorder</li>
          <li>Generalized anxiety disorder</li>
          <li>Panic disorder</li>
          <li>Obsessive-compulsive disorder</li>
          <li>Selected other psychiatric conditions (bulimia nervosa, PMDD) per provider direction</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>MAO inhibitor use within 14 days (serious interaction risk; serotonin syndrome)</li>
          <li>Pimozide or thioridazine use (QT prolongation risk)</li>
          <li>Known hypersensitivity to fluoxetine</li>
          <li>Caution with history of mania/bipolar disorder (may precipitate manic episode)</li>
          <li>Caution with seizure disorder (lowers seizure threshold)</li>
          <li>Increased suicide risk monitoring required, especially in young adults during initial treatment/dose changes</li>
          <li>Long half-life (~4–6 days for active metabolite): effects/interactions persist weeks after discontinuation</li>
          <li>Pregnancy/breastfeeding: risk–benefit assessment required (consult provider)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>GI: nausea, diarrhea, decreased appetite (common, often transient)</li>
          <li>CNS: insomnia, headache, nervousness, drowsiness, dizziness</li>
          <li>Sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction)</li>
          <li>Weight changes (loss or gain)</li>
          <li>Serotonin syndrome (rare but serious; risk with multiple serotonergic agents): agitation, confusion, tremor, hyperthermia, autonomic instability</li>
          <li>Hyponatremia (especially in older adults or with diuretics)</li>
          <li>Bleeding risk increase (especially with NSAIDs, ASA, anticoagulants)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li>PO capsule; may take with or without food (taking with food may reduce GI upset)</li>
          <li>Typically given once daily in the morning (may reduce insomnia risk)</li>
          <li>If drowsiness occurs, consider evening dosing after discussion with provider</li>
          <li>Do not abruptly discontinue: taper under medical supervision (though fluoxetine's long half-life reduces acute withdrawal compared to other SSRIs)</li>
          <li>Counsel patient on delayed onset of benefit (2–4 weeks or longer) and importance of adherence</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Mental status: mood, anxiety symptoms, suicidal ideation (especially early treatment and dose changes)</li>
          <li>Side effects: GI tolerance, sleep, sexual function, activation/agitation</li>
          <li>Watch for signs of serotonin syndrome, especially if combined with other serotonergic drugs</li>
          <li>Hyponatremia risk: monitor if symptoms develop (confusion, headache, weakness) or in high-risk patients</li>
          <li>Bleeding precautions: counsel on risk and monitor if on concurrent anticoagulants/antiplatelets</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Primarily a continuation medication; avoid initiating without robust medical oversight and ability to monitor closely</li>
          <li>Ensure patient has prior stable use and adequate supply before extended voyage</li>
          <li>Suicide risk assessment critical: limited mental health resources at sea require careful planning and communication protocols</li>
          <li>Long half-life useful for missed doses (less risk of withdrawal) but prolongs washout if switching agents</li>
          <li>Document baseline mental status, current dose, prescriber, and emergency contact plan</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (fluoxetine capsules): <a href="https://pdf.hres.ca/dpd_pm/00067668.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067668.PDF</a></li>
          <li>CAMH – Depression treatment guidelines: <a href="https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/depression" target="_blank" rel="noopener">https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/depression</a></li>
          <li>Canadian Network for Mood and Anxiety Treatments (CANMAT): <a href="https://www.canmat.org/depression" target="_blank" rel="noopener">https://www.canmat.org/depression</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
